A Study of the Natural Progression of Interstitial Lung Disease (ILD)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00470327

Enrollment

4000

Registered

2007-05-07

Start date

2005-09-01

Completion date

2030-12-01

Last updated

2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Connective Tissue Disorder, Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases, Sarcoidosis

Keywords

Interstitial lung diseases, idiopathic pulmonary fibrosis, Sarcoidosis, mRNA and cytokine expression

Brief summary

We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Interstitial lung disease

Exclusion criteria

* Does not have Interstitial lung disease

Design outcomes

Primary

Measure	Time frame	Description
Natural history of course of disease in patients with Interstitial lung disease (ILD)	Yearly	We assess mortality roughly yearly but duration is unlimited

Countries

United States

Contacts

CONTACTVanita Patel, MPH

773-702-1012

PRINCIPAL_INVESTIGATORMary E Strek, MD

University of Chicago

Outcome results